Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Ablynx
Ghent, Belgiumgildehealthcare.com ↗
- Ownership
- Private
- Employees
- ~450
- Development stage
- Commercial
01
Overview
Ablynx developed a proprietary nanobody technology platform with over eight clinical-stage programs and more than forty-five total R&D programs. Its most advanced product was caplacizumab for acquired thrombotic thrombocytopenic purpura, which completed Phase III trials and was submitted for regulatory approval in the EU prior to the Sanofi acquisition. The company’s pipeline spans multiple therapeutic areas including rare blood disorders, inflammation, oncology/immuno-oncology, and respiratory disease.
- Therapeutic areas
- OncologyPulmonologyImmunologyHematology
- Modalities
- Nanobodies (single-domain antibody fragments derived from camelid antibodies)
- Industry
- Biotech
02
Partnerships
Beyond the preview
Go deeper on Ablynx.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ablynx.